Letter to the Editor: Metabolic Changes in Patients with Schizophrenia Switched from Olanzapine to Asenaprine or Clozapine
Conclusion The relationships between the potency of 5-HT2C blockade and hypertriglyceridemia and the potency of M3 blockade and glucose intolerance were shown in clinical setting. Receptor-binging profiles might be useful to estimate metabolic effect of antipsychotics-treatment. References Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008;101: 273–286. Salvi V, Mencacci C, Barone-Adesi F. H1-histamine receptor affinity predicts weight gain with antidepressants. Eur Neuropsychopharmacol. 2016;26:1673–1677. Montastruc F, Palmaro A, Bagheri H, et al. Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: s pharmacoepidemiological-pharmacodynamic study in VigiBase. Eur Neuropsychopharmacol. 2015; 25:1556–1565. De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26:733–759. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23:65–73. Palacios JM, Pazos A, Hoyer D. A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment. Psychopharmac...
Publication date: 1 August 2020Source: Neuroscience, Volume 440Author(s): Katsumasa Muneoka, Yasunori Oda, Masaaki Iwata, Masaomi Iyo, Kenji Hashimoto, Yukihiko Shirayama
Publication date: Available online 10 July 2020Source: Clinica Chimica ActaAuthor(s): Xingzhong Hu, Dong Chen, Lianpeng Wu, Guiqing He, Wei Ye
Publication date: Available online 9 July 2020Source: Obesity Research &Clinical PracticeAuthor(s): Abdulzahra Hussain, Kamal Mahawar, Zefeng Xia, Wah Yang, Shamsi EL-Hasani
Publication date: Available online 9 July 2020Source: Meat ScienceAuthor(s): Carolina L. Gonzales, Ty E. Lawrence, John P. Hutcheson, Stephen B. Smith
Publication date: November 2020Source: Food Research International, Volume 137Author(s): Priya Tyagi, Mohd Tasleem, Shweta Prakash, Garima Chouhan
Publication date: Available online 10 July 2020Source: Food Quality and PreferenceAuthor(s): Nobu Shirai, Chizuru Take Homma, Chinatsu Kon, Tomoko Imura, Yuji Wada
Publication date: Available online 10 July 2020Source: Food ChemistryAuthor(s): Ting Xia, Wenhui Duan, Zhujun Zhang, Bin Fang, Bo Zhang, Bicheng Xu, Celia Bertha Vargas de la Cruz, Hesham El-Seedi, Jesus Simal-Gandara, Shaoyun Wang, Min Wang, Jianbo Xiao
Publication date: Available online 9 July 2020Source: Food BioscienceAuthor(s): Hai-long Zhang, Qing-xiao Wu, Xiao Wei, Xiao-ming Qin
This study used 30 adult male mice strain BALB/c. Diabetes was induced using high-fat diet/streptozotocin method until random blood glucose level reached> 200 mg/dL. Diabetic mice were then exposed to electrical field (static and dynamic), magnetic field (static and induce), and infrared ray (with or without infrared ray) combination therapy 15 min daily for 28 days. Fasting blood glucose level, plasma insulin level, HOMA-IR index, and membrane GLUT-4 density after treatment were analyzed statistically atα = 0.05. Result showed that exposure combination of electrical field, magnetic field, and infrared were found ...
The objective of this study was investigating the additional effect of DL with nonsurgical periodontal treatment on the red complex bacteria in type 2 diabetes mellitus (DM) patients with chronic periodontitis (CP). Sixty type 2 DM patients with chronic periodontitis (CP) were randomly assigned in two parallel groups to receive scaling root planning (SRP,n = 30) or SRP followed by DL periodontal pocket irradiation (SRP + DL,n = 30). Recording of clinical parameters and subgingival plaque sampling were performed at baseline, and post therapy (1 and 3 months after treatment). Amounts ofPorphy...
More News: Addiction | Bipolar | Brain | Cholesterol | Depression | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Genetics | Hyperactivity | Insulin | Internal Medicine | Invega | Japan Health | Mania | Medical Ethics | Men | Metabolic Syndrome | Neurology | Neuroscience | Obesity | Pancreas | Psychiatry | Reflex Sympathetic Dystrophy | Schizophrenia | Study | Zyprexa